Ascendis Pharma
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering...
Latest News
4 days ago · marketbeat.com
Ascendis Pharma A/S Q3 Earnings Call HighlightsAscendis Pharma A/S NASDAQ: ASND reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL grew.
4 days ago · seekingalpha.com
Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript
6 days ago · globenewswire.com
Ascendis Pharma to Participate in the Jefferies London Healthcare ConferenceCOPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at 11:30 a.m. Greenwich Mean Time (GMT) / 6:30 a.m. Eastern Time / 3:30 a.m. Pacific Time in London, United Kingdom.
11 days ago · globenewswire.com
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The designation would provide Ascendis benefits that include 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission (EC).
11 days ago · globenewswire.com
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026COPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast at 8:00 a.m. Eastern Time (ET) that day to discuss its third quarter 2026 financial results and business update.
22 days ago · globenewswire.com
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsCOPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D.
1 month ago · globenewswire.com
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenCOPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.
1 month ago · zacks.com
FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingBBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
1 month ago · globenewswire.com
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon® PTH (palopegteriparatide) over a 5-year period.
2 months ago · seekingalpha.com
Ascendis Pharma: Back To Full IndependenceAscendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and Yuviwel—show robust growth, and Yorvipath net sales should exceed $1.1 billion this year. Yuviwel's strong U.S. launch and favorable BioMarin settlement provide freedom to operate.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ASND